Literature DB >> 18004592

Seroprevalence of varicella zoster virus infection in child and adult population of Catalonia (Spain).

Lluís Salleras1, Angela Domínguez, Pere Plans, Josep Costa, Neus Cardeñosa, Núria Torner, Antoni Plasència.   

Abstract

The aim of this study was to determine the prevalence of varicella IgG antibodies in the population of Catalonia, and the variables associated. The study was carried out in 2002 in a representative sample of juvenile (5-14 years) and adult population (> or =15 years) of Catalonia (Spain). The global prevalence determined by ELISA test was 95.5% (95% CI 94.7-96.3). The prevalence increased with age, from 82% (95% CI 77.0-87.0) in the 5-9 years age up to 99.4% (95% CI 98.2-100) in >64 years of age. No statistically significant differences in the seroprevalence according to the sociodemographic variables were observed. The current strategy of vaccinating preadolescents at 12 years of age who have not suffered the disease will require more than 30 years to cover the current gap immunity in adolescents and young adults. Vaccination with two doses of vaccine for all adolescents and adults < or = 50 years who report not having suffered the disease during childhood should be considered.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18004592     DOI: 10.1007/s00430-007-0064-z

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   4.148


  26 in total

1.  Seroepidemiology of varicella-zoster virus infection in Catalonia (Spain). Rationale for universal vaccination programmes.

Authors:  L Salleras; A Domínguez; J Vidal; P Plans; M Salleras; J L Taberner
Journal:  Vaccine       Date:  2000-09-15       Impact factor: 3.641

2.  Prevalence of varicella-zoster virus infection in Singapore.

Authors:  P L Ooi; K T Goh; S Doraisingham; A E Ling
Journal:  Southeast Asian J Trop Med Public Health       Date:  1992-03       Impact factor: 0.267

3.  Seroprevalence of varicella among children and adolescents in Valencia, Spain. Reliability of the parent's reported history and the medical file for identification of potential candidates for vaccination.

Authors:  J Diez-Domingo; A Gil; M San-Martín; A González; J Esteban; J M Baldó; M V Planelles; M I Ubeda; M Graullera; A Peris; M Martínez; V Antón; D Gallego; T Alvarez; J V Villarroya; A Jubert; C Casaní; C Peidró; M García; A Ballester
Journal:  Hum Vaccin       Date:  2005-09-27

4.  Seroepidemiology of Varicella zoster in Israel prior to large-scale use of varicella vaccines.

Authors:  D I Cohen; B B Davidovici; Z Smetana; R D Balicer; E Klement; E Mendelson; M S Green
Journal:  Infection       Date:  2006-08       Impact factor: 3.553

Review 5.  Varicella.

Authors:  Ulrich Heininger; Jane F Seward
Journal:  Lancet       Date:  2006-10-14       Impact factor: 79.321

6.  The seroepidemiology of varicella in Italy.

Authors:  G Gabutti; C Penna; M Rossi; S Salmaso; M C Rota; A Bella; P Crovari
Journal:  Epidemiol Infect       Date:  2001-06       Impact factor: 2.451

7.  Seroprevalence of varicella-zoster virus in the German population.

Authors:  P Wutzler; I Färber; S Wagenpfeil; H Bisanz; A Tischer
Journal:  Vaccine       Date:  2001-10-12       Impact factor: 3.641

8.  The seroepidemiology of primary varicella-zoster virus infection in Flanders (Belgium).

Authors:  Nancy Thiry; Philippe Beutels; Ziv Shkedy; Robert Vranckx; Corinne Vandermeulen; Marie Van Der Wielen; Pierre Van Damme
Journal:  Eur J Pediatr       Date:  2002-09-24       Impact factor: 3.183

9.  Prevalence of varicella-zoster antibodies in pregnant women in Catalonia (Spain). Rationale for varicella vaccination of women of childbearing age.

Authors:  P Plans; J Costa; J Espuñes; A Plasència; L Salleras
Journal:  BJOG       Date:  2007-07-30       Impact factor: 6.531

10.  Genotypic analysis of varicella-zoster virus and its seroprevalence in Finland.

Authors:  Marjaleena Koskiniemi; Maija Lappalainen; D Scott Schmid; Elena Rubtcova; Vladimir N Loparev
Journal:  Clin Vaccine Immunol       Date:  2007-07-11
View more
  5 in total

1.  Monitoring prevalence of varicella-zoster virus clades in Germany.

Authors:  A Sauerbrei; J Stefanski; A Philipps; A Krumbholz; R Zell; P Wutzler
Journal:  Med Microbiol Immunol       Date:  2010-10-31       Impact factor: 3.402

2.  Seroprevalence of antibodies against measles, rubella, mumps, varicella-zoster, and B. Pertussis in young adults of Madrid, Spain.

Authors:  Alba González-Escalada; Laura García-García; Pablo Viguera-Ester; Patricia Marín-García; Jesus García; Angel Gil-de-Miguel; Ruth Gil-Prieto
Journal:  Hum Vaccin Immunother       Date:  2013-06-21       Impact factor: 3.452

3.  Evaluation of three commercial varicella-zoster virus IgG enzyme-linked immunosorbent assays in comparison to the fluorescent-antibody-to-membrane-antigen test.

Authors:  Andreas Sauerbrei; Anna Schäfler; Jörg Hofmann; Michael Schacke; Bernd Gruhn; Peter Wutzler
Journal:  Clin Vaccine Immunol       Date:  2012-06-20

4.  Herpes zoster and postherpetic neuralgia in Catalonia (Spain).

Authors:  Luis Salleras; Montse Salleras; Patricia Salvador; Núria Soldevila; Andreu Prat; Patricio Garrido; Angela Domínguez
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

5.  Estimation of the burden of varicella in Europe before the introduction of universal childhood immunization.

Authors:  Margarita Riera-Montes; Kaatje Bollaerts; Ulrich Heininger; Niel Hens; Giovanni Gabutti; Angel Gil; Bayad Nozad; Grazina Mirinaviciute; Elmira Flem; Audrey Souverain; Thomas Verstraeten; Susanne Hartwig
Journal:  BMC Infect Dis       Date:  2017-05-18       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.